Publications by authors named "Jan Vercammen"

Claim this Profile
M
Mixed-methods evaluation of a multifaceted heart failure intervention in general practice: the OSCAR-HF pilot study.
Miek Smeets, Willem Raat, Bert Aertgeerts, Joris Penders, Jan Vercammen

ESC Heart Fail· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of an extended audit on identifying heart failure patients in general practice: baseline results of the OSCAR-HF pilot study.
Miek Smeets, Bert Vaes, Bert Aertgeerts, Willem Raat, Joris Penders, Jan Vercammen

ESC Heart Fail· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring.
Wilfried Mullens, Pieter Martens, Omid Forouzan, Jeroen Dauw, Jan Vercammen

ESC Heart Fail· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising standards of care of heart failure in general practice the OSCAR-HF pilot study protocol.
Miek Smeets, Bert Aertgeerts, Wilfried Mullens, Joris Penders, Jan Vercammen

Acta Cardiol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
Pieter Martens, Dieter Nuyens, Maximo Rivero-Ayerza, Hugo Van Herendael, Jan Vercammen

Clin Res Cardiol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry.
Frank Cools, Bart Wollaert, Geert Vervoort, Stefan Verstraete, Joeri Voet, Jan Vercammen

Acta Cardiol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure.
Pieter Martens, Jan Vercammen, Wendy Ceyssens, Linda Jacobs, Evert Luwel

ESC Heart Fail· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aggressive extensive cardiac mass in an HIV-1-infected patient: should we go for comfort therapy?
Delphine Mtf Vervloet, Michel De Pauw, Laurent Demulier, Jan Vercammen, Wim Terryn

Acta Clin Belg· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.
Frederik H Verbrugge, Jeroen Vrijsen, Jan Vercammen, Lars Grieten, Matthias Dupont

Acta Cardiol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asymptomatic episodes of device-registered atrial tachyarrhythmia are not associated with worse cardiac resynchronization therapy response.
Frederik Hendrik Verbrugge, Petra Nijst, Hugo Van Herendael, Philip De Vusser, Linda Jacobs, Jan Vercammen

Europace· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of transmural disease management in patients admitted with advanced heart failure.
Jürgen Duchenne, Frederik H Verbrugge, Matthias Dupont, Jan Vercammen, Linda Jacobs

Acta Cardiol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response.
Frederik Hendrik Verbrugge, Matthias Dupont, Jan Vercammen, Linda Jacobs, David Verhaert

Heart· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to cardiac resynchronization therapy in elderly patients (≥70 years) and octogenarians.
Frederik H Verbrugge, Matthias Dupont, Philippe De Vusser, Maximo Rivero-Ayerza, Hugo Van Herendael, Jan Vercammen

Eur J Heart Fail· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidity significantly affects clinical outcome after cardiac resynchronization therapy regardless of ventricular remodeling.
Frederik H Verbrugge, Matthias Dupont, Maximo Rivero-Ayerza, Philippe de Vusser, Hugo Van Herendael, Jan Vercammen

J Card Fail· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of adjunctive heart failure optimization immediately after implantation to improve long-term outcomes with cardiac resynchronization therapy.
Wilfried Mullens, Jacek Kepa, Philippe De Vusser, Jan Vercammen, Maximo Rivero-Ayerza

Am J Cardiol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis